title: Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate.
abstract: OBJECTIVE
  To evaluate the cardiovascular (CV) complications associated with orchiectomy (OE) and parenteral polyestradiol phosphate (PEP) therapy (240 mg/month), taking into account the effect of pretreatment diseases and pretreatment medication.
  
  
  METHODS
  A total of 244 T3-4 M0 patients and 200 T1-4 M1 patients were randomized to either OE or PEP therapy. The two groups of patients were analyzed separately. The follow-up period was 36 months. The effect of pretreatment vascular and other diseases and pretreatment medication which may be associated with a risk of CV complications was evaluated.
  
  
  RESULTS
  In the T3-4 M0 patients, the treatment (PEP versus OE) and the presence of pretreatment vascular diseases were statistically significantly associated with a risk of CV complications (p=0.01 and 0.003, respectively). In the T1-4 M1 patients, such an association was not found. No association was observed between pretreatment medication and CV complications. There was no difference in progression-free time between the therapy groups in either the T3-4 M0 or T1-4 M1 patients.
  
  
  CONCLUSIONS
  In patients with locally advanced prostatic cancer, PEP therapy is associated with a statistically significantly higher risk of CV complications compared to OE.
authors.affiliation: Department of Urology, Helsinki University Central Hospital, Helsinki, Finland. arto.mikkola@hus.fi
authors.forename: Arto
authors.initials: A
authors.lastname: Mikkola
authors.forename: Jussi
authors.initials: J
authors.lastname: Aro
authors.forename: Sakari
authors.initials: S
authors.lastname: Rannikko
authors.forename: Hanna
authors.initials: H
authors.lastname: Oksanen
authors.forename: Mirja
authors.initials: M
authors.lastname: Ruutu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy / Q000009:adverse effects*; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004958:Estradiol; C008958:polyestradiol phosphate